DMTs: short summaries

This section is still in development. Where an MS-Selfie summary is not yet available, links to the manufacturers’ patient information leaflets are provided.

Alemtuzumab

(Lemtrada)

Anti-CD20s (ocrelizumab, ofatumumab, ublituximab) – summary to follow

(Ocrevus, Kesimpta, Briumvi)

Cladribine

(Mavenclad)

Fumarates (dimethyl fumarate and diroximel fumarate)

(Tecfidera, Vumerity)

Glatiramer acetate (GA)

(Copaxone, Brabio)

HSCT

(Haematopoietic stem cell transplant)

Interferon-beta (IFN-beta)

(Avonex, Betaferon, Betaseron, Extavia, Plegridy, Rebif)

Mitoxantrone

(Novantrone)

Natalizumab

(Tysabri)

Sphingosine 1-phosphate (S1P) modulators (fingolimod, siponimod, ozanimod, ponesimod)

(Gilenya, Mayzent, Zeposia, Ponvory)

Teriflunomide

(Aubagio)

The link below takes you out of the MS-Selfie website to Prof G’s MS-Selfie newsletter and research archive.

Is it ethical to use teriflunomide as an active comparator in phase 3 trials?